LONDON – Ablynx NV signed an $840 million licensing deal with Abbvie Inc. for its ALX-0061 nanobody targeted against the cytokine interleukin-6 receptor (IL-6R), in the treatment of rheumatoid arthritis and systemic lupus erythematosus.